CCL2 and neoplasm: Together, these results suggest that the combination of shTRAIL with a CCL2 inhibitor results in improved antitumor effects by remodeling the tumor immune microenvironment, thus demonstrating the therapeutic benefit of combining shTRAIL with the chemotherapeutic trabectedin and underscoring the potential of this approach for clinical translation.